← Back to Search

Monoclonal Antibodies

IMC-002 for Lymphoma

Phase 1
Waitlist Available
Research Sponsored by ImmuneOncia Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing IMC-002, a new drug, in adults with advanced or recurring cancers. Researchers aim to understand how the drug works in the body and its effects on cancer.

Eligible Conditions
  • Lymphoma
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: IMC-002Experimental Treatment1 Intervention
Dose escalation will follow the traditional 3+3 design.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMC-002
2020
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

ImmuneOncia Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
117 Total Patients Enrolled
1 Trials studying Lymphoma
23 Patients Enrolled for Lymphoma
HEUNG TAE KIMStudy DirectorImmuneOncia Therapeutics Inc.
Ji Hye LeeStudy DirectorImmuneOncia Therapeutics Inc.
1 Previous Clinical Trials
23 Total Patients Enrolled
1 Trials studying Lymphoma
23 Patients Enrolled for Lymphoma
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top